Pages

FDA faces a reputation crisis amid Trump pressure for fast COVID action—and that's bad news for pharma

FDA faces a reputation crisis amid Trump pressure for fast COVID action—and that's bad news for pharma: The flip-flop emergency approval of convalescent plasma by the FDA sparked a social media wildfire of criticism—and cast a shadow on the agency’s reputation. Many criticized the FDA and Commissioner Stephen Hahn over the plasma EUA for COVID-19 patients and the appearance of President Trump's involvement.

How the FDA continues to fail vulnerable patients

How the FDA continues to fail vulnerable patients: For the first time in recent memory, the FDA is moving at a record pace to remove barriers and speed approval to provide treatment options and a vaccine for COVID-19.

 

Compounder SCA Pharma recalls heparin products over ...

5 days ago - SCA Pharma set out to expand capacity for key drugs earlier this summer. Now, the compounding pharmacy is pulling one of its critical meds—common blood .

 

FDA's Compounding Memorandum of Understanding with ...

4 days ago - The MOU also defines the statutory term of “inordinate amounts” as it relates to the proportion of compounded drugs that may be distributed interstate for ..

 

Compounding Quality Center of Excellence: Self-Guided ...

5 days ago - The Compounding Quality Center of Excellence offers free online training courses on quality manufacturing practice requirements and compounding policies .

 

Health Crisis Highlights Value of Pharmacy Compounding ...

6 days ago - In the era of coronavirus disease 2019 (COVID-19), pharmaceutical compounding is as vital as ever.

 

1 day ago - The guidance documents permit compounding by outsourcing facilities registered with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act, as

 

21 hours ago - Compounding of medications, such as crushing tablets and dispersing the contents of capsules, is a common practice in pharmacies and hospitals worldwide ...

 

 

 

 

Resources for Animal Food Producers in Southeast and Gulf Coasts Affected by Storms Marco and Laura

 

Resources for Animal Food Producers in Southeast and Gulf Coasts Affected by Storms Marco and Laura
As storms Marco and Laura approach the Southeast and Gulf Coasts of the United States, the U.S. Food and Drug Administration’s Center for Veterinary Medicine reminds those who may be affected by storm waters about resources available for animal food producers who may be harvesting, mixing, storing or distributing grains and other foods for animals.

The FDA reminds harvesters that crops harvested from flooded fields are often unacceptable because of contamination. Flood waters, which are different from pooled rain water, may contain sewage, pathogenic organisms, pesticides, chemical wastes, or other toxic substances. Mold growth is another serious concern for flood impacted crops intended for use in animal food. Some molds produce mycotoxins, which are toxic to certain animals and people.

Health Standards to Advance Transparency, Integrity, Science, Technology Infrastructure, and Confidential Statistics Act of 2020 (Health STATISTICS Act) - H.R.8080.

The House of Representatives has introduced a new bill, the "Health Standards to Advance Transparency, Integrity, Science, Technology Infrastructure, and Confidential Statistics Act of 2020 (Health STATISTICS Act) - H.R.8080."  The bill would direct the United States Department of Health and Human Services to share health data it collects from reporting entities with collected the Centers for Disease Control and Prevention, other public health agencies, and the public.  The bill would also require that the individual's privacy be maintained.

U.N. cautions that virus plasma treatment still experimental

 

The World Health Organization on Monday cautioned that using blood plasma from COVID-19 survivors to treat other patients is still considered an experimental therapy, voicing the concern as a U.S. boost for the treatment has many scientists afraid formal studies will be derailed.

READ MORE >

Tuesday, August 18, 2020

 

 

 

The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response to the COVID-19 pandemic:

  • The FDA issued Yale School of Public Health an emergency use authorization (EUA) for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19. This molecular test is for the qualitative detection of nucleic acid from SARS-CoV-2 in saliva collected without preservatives in a sterile container from individuals suspected of COVID-19 by their healthcare provider. SalivaDirect does not require any special type of swab or collection device – a saliva sample can be collected in any sterile container. It is also unique because it does not require a separate nucleic acid extraction step. This is significant because the extraction kits used for this step in other tests have been prone to shortages in the past.
  • As part of the FDA’s effort to protect consumers, the agency issued a joint warning letter with the Federal Trade Commission to SilveryGuy, a company that participates in the Amazon Associates program, for selling fraudulent COVID-19 related products. As an Amazon associate, the company earns commissions by promoting the sale of Colloidal Silver products on the company’s website, with misleading claims that the product can mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Currently, there are no FDA-approved products to prevent or treat COVID-19. Consumers concerned about COVID-19 should consult with their health care provider.
  • Testing updates:
  • To date, the FDA has currently authorized 214 tests under EUAs; these include 175 molecular tests, 37 antibody tests, and 2 antigen tests.

Coronavirus outbreak: FDA flags accuracy problem with widely used coronavirus test

 


Live updates from Modern Healthcare on the coronavirus outbreak and how COVID-19 is affecting the healthcare industry.

READ MORE >

Sunday, August 16, 2020

 FDA finds new toxic hand-sanitizer ingredient, expands warning to 157 products

Regulators find toxic 1-propanol as well as methanol in some products.

Read in Ars Technica: https://apple.news/AnQKofJihTASJZY2fNrVaQg

Former Vance AFB Major Sentenced to Two Years in Federal Prison for Taking Kickbacks Involving Compounding Pharmacies. Major she gave military members pre-printed prescription pads and induced them to ask their doctors for specific compounded drugs. The Major admitted she then sent the prescriptions or caused them to be sent to specific pharmacies.

 Department of Justice

U.S. Attorney’s Office
Western District of Oklahoma

FOR IMMEDIATE RELEASE
Monday, August 10, 2020

Former Vance AFB Major Sentenced to Two Years in Federal Prison for Taking Kickbacks Involving Compounding Pharmacies

OKLAHOMA CITY – ROMEATRIUS MOSS, 40, a nurse and former Air Force Major stationed at Vance Air Force Base in Enid, Oklahoma, was sentenced today to serve 24 months in prison for health care fraud in which she accepted kickbacks for referring TRICARE beneficiaries to pharmacies furnishing compounded drugs, announced U.S. Attorney Timothy J. Downing.  Moss was also ordered to pay restitution in the amount of $622,459.00.

According to a felony information filed on September 30, 2019, Moss solicited and received $73,823.06 in return for referring prescriptions for members of the U.S. military to compounding pharmacies that were reimbursed by TRICARE, a health insurance program for military members.  Because of resulting cost increases and infringement on patient choice, it is a crime to solicit or receive payments for referrals to health care providers for an item or service that could be paid, in whole or in part, by a federal health care program.

Moss pleaded guilty on October 15, 2019, before U.S. District Judge Patrick R. Wyrick.  She admitted that while she was employed in the medical unit at Vance AFB, she gave military members pre-printed prescription pads and induced them to ask their doctors for specific compounded drugs.  Moss admitted she then sent the prescriptions or caused them to be sent to specific pharmacies.  Moss admitted she was paid a kickback that was a percentage of the gross reimbursement the pharmacies received from TRICARE for filling the prescriptions.

Today, Judge Wyrick sentenced Moss to 24 months in the custody of the Bureau of Prisons, followed by three years of supervised release.  Judge Wyrick also ordered Moss to pay restitution to TRICARE in the amount of $622,459.00, the total amount of kickbacks she received in the referral scheme.  She was also ordered to forfeit her residence in Enid.

The case is the result of an investigation by the Defense Criminal Investigative Service, the Air Force’s Office of Special Investigations, and the Federal Bureau of Investigation–Oklahoma City Division.  Assistant U.S. Attorneys Jessica Perry and Amanda Maxfield Green prosecuted the case.

Reference is made to court filings for further information.  To download a photo of U.S. Attorney Downing, click here.

Topic(s): 
Health Care Fraud